These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

263 related articles for article (PubMed ID: 27615411)

  • 81. Clinical experience with pirfenidone in five patients with scleroderma-related interstitial lung disease.
    Miura Y; Saito T; Fujita K; Tsunoda Y; Tanaka T; Takoi H; Yatagai Y; Rin S; Sekine A; Hayashihara K; Nei T; Azuma A
    Sarcoidosis Vasc Diffuse Lung Dis; 2014 Oct; 31(3):235-8. PubMed ID: 25363224
    [TBL] [Abstract][Full Text] [Related]  

  • 82. Pirfenidone induced phototoxic reaction in an elderly man.
    Gaikwad RP; Mukherjee SS
    Indian J Dermatol Venereol Leprol; 2016; 82(1):101-3. PubMed ID: 26728829
    [No Abstract]   [Full Text] [Related]  

  • 83. Two distinct clinical types of interstitial lung disease associated with polymyositis-dermatomyositis.
    Won Huh J; Soon Kim D; Keun Lee C; Yoo B; Bum Seo J; Kitaichi M; Colby TV
    Respir Med; 2007 Aug; 101(8):1761-9. PubMed ID: 17428649
    [TBL] [Abstract][Full Text] [Related]  

  • 84. Cytokine profiles in polymyositis and dermatomyositis complicated by rapidly progressive or chronic interstitial lung disease.
    Gono T; Kaneko H; Kawaguchi Y; Hanaoka M; Kataoka S; Kuwana M; Takagi K; Ichida H; Katsumata Y; Ota Y; Kawasumi H; Yamanaka H
    Rheumatology (Oxford); 2014 Dec; 53(12):2196-203. PubMed ID: 24970922
    [TBL] [Abstract][Full Text] [Related]  

  • 85. Utility of anti-melanoma differentiation-associated gene 5 antibody measurement in identifying patients with dermatomyositis and a high risk for developing rapidly progressive interstitial lung disease: a review of the literature and a meta-analysis.
    Chen Z; Cao M; Plana MN; Liang J; Cai H; Kuwana M; Sun L
    Arthritis Care Res (Hoboken); 2013 Aug; 65(8):1316-24. PubMed ID: 23908005
    [TBL] [Abstract][Full Text] [Related]  

  • 86. Antacid Therapy and Disease Progression in Patients with Idiopathic Pulmonary Fibrosis Who Received Pirfenidone.
    Kreuter M; Spagnolo P; Wuyts W; Renzoni E; Koschel D; Bonella F; Maher TM; Kolb M; Weycker D; Kirchgässler KU; Costabel U
    Respiration; 2017; 93(6):415-423. PubMed ID: 28399537
    [TBL] [Abstract][Full Text] [Related]  

  • 87. Pirfenidone combined with corticosteroids in a patient with systemic lupus erythematosus-associated interstitial lung disease.
    Yang BB; Man XY; Zheng M
    J Eur Acad Dermatol Venereol; 2017 Sep; 31(9):e388-e389. PubMed ID: 28261880
    [No Abstract]   [Full Text] [Related]  

  • 88. Impact of the Combined Immunosuppressive Therapy on Different Mortality Score Groups in Amyopathic Dermatomyositis-Associated Interstitial Lung Disease and the Problem of Sample Splitting.
    Waki D; Nishimura K
    Chest; 2021 Feb; 159(2):882-883. PubMed ID: 33563444
    [No Abstract]   [Full Text] [Related]  

  • 89. [Clinically amyotrophic dermatomyositis with fatal interstitial lung disease].
    Bernez A; Machet L; Diot P; Legras A; Vaillant L; Lorette G
    Ann Dermatol Venereol; 2005 Jan; 132(1):52-3. PubMed ID: 15746612
    [No Abstract]   [Full Text] [Related]  

  • 90. Fatal rapidly progressive interstitial lung disease in a patient with amyopathic dermatomyositis.
    Mobeireek A; Conca W; Mohammed S; AlObaid F; AlHajji M
    Ann Thorac Med; 2021; 16(3):294-298. PubMed ID: 34484446
    [TBL] [Abstract][Full Text] [Related]  

  • 91. Treatment of clinically amyopathic dermatomyositis in adults: a systematic review.
    Callander J; Robson Y; Ingram J; Piguet V
    Br J Dermatol; 2018 Dec; 179(6):1248-1255. PubMed ID: 27167896
    [TBL] [Abstract][Full Text] [Related]  

  • 92. Pirfenidone in rheumatoid arthritis-associated interstitial lung disease.
    Graudal N; Nielsen CT; Lindhardsen J
    Lancet Respir Med; 2023 Jun; 11(6):e51. PubMed ID: 37003283
    [No Abstract]   [Full Text] [Related]  

  • 93. Update in diffuse parenchymal lung disease 2011.
    Luckhardt TR; Müller-Quernheim J; Thannickal VJ
    Am J Respir Crit Care Med; 2012 Jul; 186(1):24-9. PubMed ID: 22753686
    [No Abstract]   [Full Text] [Related]  

  • 94. Pirfenidone in rheumatoid arthritis-associated interstitial lung disease - Authors' reply.
    Hurwitz S; Maurer R; Solomon JJ; Rosas IO
    Lancet Respir Med; 2023 Jun; 11(6):e52. PubMed ID: 37003284
    [No Abstract]   [Full Text] [Related]  

  • 95. Re: A controlled clinical trial with pirfenidone in the treatment of pathological skin scarring caused by burns in pediatric patients.
    Freshwater MF
    Ann Plast Surg; 2012 Jul; 69(1):111; author reply 111-2. PubMed ID: 22705672
    [No Abstract]   [Full Text] [Related]  

  • 96. A trial of pirfenidone in hospitalized adult patients with severe coronavirus disease 2019.
    Zhang F; Wei Y; He L; Zhang H; Hu Q; Yue H; He J; Dai H
    Chin Med J (Engl); 2021 Dec; 135(3):368-370. PubMed ID: 34855641
    [No Abstract]   [Full Text] [Related]  

  • 97. A Randomized Phase 1 Evaluation of Deupirfenidone, a Novel Deuterium-Containing Drug Candidate for Interstitial Lung Disease and Other Inflammatory and Fibrotic Diseases.
    Chen MC; Korth CC; Harnett MD; Elenko E; Lickliter JD
    Clin Pharmacol Drug Dev; 2022 Feb; 11(2):220-234. PubMed ID: 34779583
    [TBL] [Abstract][Full Text] [Related]  

  • 98. Effect of antifibrotics on short-term outcome after bilateral lung transplantation: a multicentre analysis.
    Lambers C; Boehm PM; Lee S; Ius F; Jaksch P; Klepetko W; Tudorache I; Ristl R; Welte T; Gottlieb J
    Eur Respir J; 2018 Jun; 51(6):. PubMed ID: 29678942
    [No Abstract]   [Full Text] [Related]  

  • 99. Home spirometry to assess efficacy of pirfenidone in progressive unclassifiable interstitial lung disease: better the devil you know than the devil you don't.
    Sgalla G; Mari PV; Richeldi L
    Ann Transl Med; 2020 Dec; 8(23):1615. PubMed ID: 33437814
    [No Abstract]   [Full Text] [Related]  

  • 100. Interstitial lung disease: perhaps unclassifiable, but not untreatable.
    Oldham JM
    Lancet Respir Med; 2020 Feb; 8(2):126-127. PubMed ID: 31578170
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.